Key result
In patients with acute ischemic stroke or TIA and nonvalvular atrial fibrillation, DOACs showed a similar 2-year risk of stroke or systemic embolism compared to warfarin, but lower risks of death and intracranial hemorrhage.
Why the study?
Do DOACs reduce stroke or systemic embolism in patients with acute ischemic stroke or TIA and nonvalvular atrial fibrillation compared to warfarin?
Observational (n=1,116)
Yes
Do DOACs reduce stroke or systemic embolism in patients with acute ischemic stroke or TIA and nonvalvular atrial fibrillation compared to warfarin?
In Japanese patients with acute ischemic stroke or TIA and NVAF, DOACs showed similar efficacy for preventing stroke or systemic embolism but significantly lower risks of intracranial hemorrhage and death compared to warfarin over 2 years.
Answers are grounded in this paper and cite their sources.
May favor DOACs for lower ICH and mortality in acute stroke AF; leaves open RCT confirmation of stroke prevention equivalence.
BACKGROUND: We determined the 2-year long-term risk-benefit profile in patients with stroke or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry in Japan. METHODS AND RESULTS: and discharge modified Rankin Scale scores than warfarin users (P<0.0001 each). Incidences of stroke/systemic embolism (adjusted hazard ratio, 1.07; 95% CI, 0.66-1.72), all ischemic events (1.13; 0.72-1.75), and ischemic stroke/TIA (1.58; 0.95-2.62) were similar between groups. Risks of intracranial hemorrhage (0.32; 0.09-0.97) and death (0.41; 0.26-0.63) were significantly lower for DOAC users. Infection was the leading cause of death, accounting for 40% of deaths among warfarin users. CONCLUSIONS: Stroke/TIA patients receiving DOACs for secondary prevention were younger and had lower stroke severity and risk indices than those receiving warfarin. Estimated cumulative incidences of stroke and systemic embolism within 2 years were similar between warfarin and DOACs users, but those of death and intracranial hemorrhage were significantly lower among DOAC users.
No takes yet. Share an insight, caveat, or question.
Yoshimura et al. (2018) conducted an observational in Nonvalvular atrial fibrillation with acute ischemic stroke or TIA (n=1,116). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Stroke or systemic embolism by 2 years (HR 1.07, 95% CI 0.66-1.72). In patients with acute ischemic stroke or TIA and nonvalvular atrial fibrillation, DOACs showed a similar 2-year risk of stroke or systemic embolism compared to warfarin, but lower risks of death and intracranial hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: